112 related articles for article (PubMed ID: 21159616)
1. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer.
Tsimberidou AM; Akerley W; Schabel MC; Hong DS; Uehara C; Chhabra A; Warren T; Mather GG; Evans BA; Woodland DP; Swabb EA; Kurzrock R
Mol Cancer Ther; 2010 Dec; 9(12):3410-9. PubMed ID: 21159616
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
[TBL] [Abstract][Full Text] [Related]
5. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
8. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP
Invest New Drugs; 2019 Aug; 37(4):674-683. PubMed ID: 30411218
[TBL] [Abstract][Full Text] [Related]
9. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
14. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Royce ME; Hoff PM; Dumas P; Lassere Y; Lee JJ; Coyle J; Ducharme MP; De Jager R; Pazdur R
J Clin Oncol; 2001 Mar; 19(5):1493-500. PubMed ID: 11230496
[TBL] [Abstract][Full Text] [Related]
16. Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors.
Shiah HS; Chiang NJ; Lin CC; Yen CJ; Tsai HJ; Wu SY; Su WC; Chang KY; Wang CC; Chang JY; Chen LT
Oncologist; 2021 Apr; 26(4):e567-e579. PubMed ID: 33245172
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
18. A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
Wang-Gillam A; Arnold SM; Bukowski RM; Rothenberg ML; Cooper W; Wang KK; Gauthier E; Lockhart AC
Invest New Drugs; 2012 Feb; 30(1):266-72. PubMed ID: 20697774
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks.
Yamamoto N; Andoh M; Kawahara M; Fukuoka M; Niitani H
Cancer Sci; 2009 Feb; 100(2):316-21. PubMed ID: 19068085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]